I missed it (really wasn't following the company), but I think there's a lot of smoke and no fire here. Looks like a momentum run on a tiny biotech. All it took was a PR on a phase II trial, but as they say the devil is in the details. Be very careful with this one.
As I've noted in the past, if you want to follow biotechs on IH DD's board is about the best to read, many very capable people with biotech and medical backgrounds post, and they do great research work.
If you work hard and have a skill set to match success and wealth is yours for the taking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.